SAN JOSE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) , announced today the launch of the BD FACSAria(TM) III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.
“As the pioneer in flow cytometry, BD Biosciences’ goal is to expand the range of applications that can benefit from this technology by building innovative, powerful tools that are easier to use and more accessible to a larger number of life science researchers,” said James Glasscock, President, BD Biosciences - Cell Analysis. “The new BD FACSAria III system reflects this effort by providing researchers the flexibility to configure a system that meets their application requirements and budgets today, with the ability to expand its capabilities later to meet future needs.”
Innovations in the new BD FACSAria III Cell Sorting System include:
For more information on the BD FACSAria III Cell Sorting System, please visit: www.bdbiosciences.com/aria
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
CONTACT: Jeff Ezell, Public Relations, +1-201-847-5533, jeff_ezell@bd.com
Web site: http://www.bd.com/
